AI Article Synopsis
- Stereotactic body radiation therapy (SBRT) has shown potential as a more effective treatment for advanced hepatocellular carcinoma (HCC) compared to the standard drug sorafenib, particularly in terms of overall survival rates.
- A study analyzed data from 1,023 patients, revealing that those who received SBRT had a median overall survival of 18.1 months versus 8.8 months for those on sorafenib.
- SBRT particularly improved survival in patients with intrahepatic lesions and extrahepatic metastases, but did not show benefits for patients with portal vein thrombosis.
Article Abstract
Background And Aims: Stereotactic body radiation therapy (SBRT) has emerged as a safe and effective treatment for patients with hepatocellular carcinoma (HCC), but its role in patients with advanced HCC is not yet defined. In this study, we aim to assess the efficacy and safety of SBRT in comparison to sorafenib treatment in patients with advanced HCC.
Methods: We included 901 patients treated with sorafenib at six tertiary centers in Europe and Asia and 122 patients treated with SBRT from 13 centers in Germany and Switzerland. Medical records were reviewed including laboratory parameters, treatment characteristics and development of adverse events. Propensity score matching was performed to adjust for differences in baseline characteristics. The primary endpoint was overall survival (OS) and progression-free survival.
Results: Median OS of SBRT patients was 18.1 (10.3-25.9) months compared to 8.8 (8.2-9.5) in sorafenib patients. After adjusting for different baseline characteristics, the survival benefit for patients treated with SBRT was still preserved with a median OS of 17.0 (10.8-23.2) months compared to 9.6 (8.6-10.7) months in sorafenib patients. SBRT treatment of intrahepatic lesions in patients with extrahepatic metastases was also associated with improved OS compared to patients treated with sorafenib in the same setting (17.0 vs. 10.0 months, = 0.012), whereas in patients with portal vein thrombosis there was no survival benefit in patients with SBRT.
Conclusions: In this retrospective comparative study, SBRT showed superior efficacy in HCC patients compared to patients treated with sorafenib.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738268 | PMC |
| http://dx.doi.org/10.1159/000490260 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review.
Leuk Lymphoma
January 2025
Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Follicular lymphoma (FL) represents the second most frequent type of non-Hodgkin lymphoma and the most common indolent histology. The disease course of FL is heterogeneous, likely resulting from diverse molecular and immunological features that drive a broad spectrum of clinical presentations. While some patients with low-volume and asymptomatic disease are suitable for observation, patients with high tumor burden, advanced-stage, or symptomatic disease more often necessitate treatment initiation.
View Article and Find Full Text PDFReal-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.
Leuk Lymphoma
January 2025
Multiple Myeloma Division, The John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, USA.
Patients participating in clinical trials are highly selected and may not represent the general population. The pivotal study of teclistamab (MajesTEC-1), a B-cell maturation antigen (BCMA)xCD3 bispecific antibody, demonstrated impressive response rates and progression free survival in relapsed/refractory multiple myeloma (RRMM) with acceptable toxicity. We performed a retrospective study of 58 patients treated as standard of care at four US academic centers to determine how these results translated to the real-world.
View Article and Find Full Text PDFSelf-esteem, defense mechanisms, sexual satisfaction and stress coping mechanisms in individuals treated for vaginismus: A controlled study.
Afr J Reprod Health
November 2024
Faculty of Medicine, Kocaeli University, Turkey.
The aim of study was to analyze the extent to which treatment for vaginismus affect self-esteem, defense mechanisms, sexual satisfaction and coping with stress. Was conducted as aquasi-experimental, cross-sectional study. The population of the study consisted of womenwho were followed up with the diagnosis of vaginismus in obstetrics clinic.
View Article and Find Full Text PDFIliac Crest Bone Graft and Fascia Lata Free Flap for Rescue of Mandibular Osteoradionecrosis.
Otolaryngol Head Neck Surg
January 2025
Section of Facial Plastic and Microvascular Surgery, Cleveland Clinic, Cleveland, Ohio, USA.
Objective: Describe the use, indications, and outcomes of iliac crest bone graft (ICBG) with concomitant anterolateral thigh fascia lata (ALTFL) rescue flap for the management of mandibular osteoradionecrosis (ORN).
Study Design: Retrospective chart review.
Setting: Single institution.
A case of late-onset sinusoidal obstruction syndrome diagnosed histologically before meeting diagnostic criteria.
Int J Hematol
January 2025
Department of Hematology, Nagaoka Red Cross Hospital, 2-297-1, Senshu, Nagaoka, 940-2085, Japan.
Sinusoidal obstruction syndrome (SOS), also known as hepatic veno-occlusive disease (VOD), is a life-threatening complication of hematopoietic stem cell transplantation. In severe cases, SOS/VOD progresses to multiple organ failure with a mortality rate higher than 80%. Early diagnosis and treatment based on severity assessment improve the prognosis of severe SOS/VOD, but conventional diagnostic criteria may be insufficient for an early diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!